The haemoglobinopathy survey: The reality of transfusion practice in sickle cell disease and thalassaemia in England.
alloimmunisation
antibodies
crossmatch
exchange transfusion
red cell genotype
sickle cell
thalassaemia
transfusion
Journal
Transfusion medicine (Oxford, England)
ISSN: 1365-3148
Titre abrégé: Transfus Med
Pays: England
ID NLM: 9301182
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
received:
17
04
2020
revised:
08
09
2020
accepted:
28
09
2020
pubmed:
27
10
2020
medline:
7
10
2021
entrez:
26
10
2020
Statut:
ppublish
Résumé
To establish, in an unselected population of London haemoglobinopathy patients, transfusion requirements, blood antigens/alloantibodies, transfusion modalities, burden of transfusion reactions and donor exposure. Haemoglobinopathy patients are among the most highly transfused patient populations, and the overall population and number of patients on long-term transfusion programmes are increasing. To provide a safe and efficacious transfusion service for patients, it is important to understand current practice, morbidity associated with transfusion, efficacy of different transfusion modalities and geno-/phenotype requirements. Data on 4451 transfusion episodes in 760 patients from 12 London hospitals were collected retrospectively over a 6-month period in 2011. Alloimmunisation prevalence was 17% for sickle cell disease (SCD) and 22% for thalassaemia, most commonly anti-Rh/Kell/Kp Transfusion modality choice was influenced by the resources available-children mostly received simple transfusions, and adults received erythrocytapheresis; the relationships between frequency of exchanges/transfusion modality/target HbA% were not simple, possibly reflecting the difference in recipient erythropoiesis and consequent transfusion modality selection bias; adherence to existing and current guidelines regarding geno-/phenotyping was limited; and alloimmunisation had a low incidence and high prevalence in both disorders.
Sections du résumé
OBJECTIVES
OBJECTIVE
To establish, in an unselected population of London haemoglobinopathy patients, transfusion requirements, blood antigens/alloantibodies, transfusion modalities, burden of transfusion reactions and donor exposure.
BACKGROUND
BACKGROUND
Haemoglobinopathy patients are among the most highly transfused patient populations, and the overall population and number of patients on long-term transfusion programmes are increasing. To provide a safe and efficacious transfusion service for patients, it is important to understand current practice, morbidity associated with transfusion, efficacy of different transfusion modalities and geno-/phenotype requirements.
METHODS
METHODS
Data on 4451 transfusion episodes in 760 patients from 12 London hospitals were collected retrospectively over a 6-month period in 2011.
RESULTS
RESULTS
Alloimmunisation prevalence was 17% for sickle cell disease (SCD) and 22% for thalassaemia, most commonly anti-Rh/Kell/Kp
CONCLUSION
CONCLUSIONS
Transfusion modality choice was influenced by the resources available-children mostly received simple transfusions, and adults received erythrocytapheresis; the relationships between frequency of exchanges/transfusion modality/target HbA% were not simple, possibly reflecting the difference in recipient erythropoiesis and consequent transfusion modality selection bias; adherence to existing and current guidelines regarding geno-/phenotyping was limited; and alloimmunisation had a low incidence and high prevalence in both disorders.
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
456-466Informations de copyright
© 2020 British Blood Transfusion Society.
Références
Chou ST, Liem RI, Thompson AA. Challenges of alloimmunization in patients with haemoglobinopathies. Br J Haematol. 2012;159:394-404.
Singer ST, Wu V, Mignacca R, Kuypers FA, Morel P, Vichinsky EP. Alloimmunization and erythrocyte autoimmunization in transfusion-dependent thalassemia patients of predominantly asian descent. Blood. 2000;96:3369-3373.
Elhence P, Solanki A, Verma A. Red blood cell antibodies in thalassemia patients in northern India: risk factors and literature review. Indian J Hematol Blood Transfus. 2014;30:301-308.
British Committee for Standards in Haematology. Guidelines for pre-transfusion compatibility procedures in blood transfusion laboratories. British Committee for Standards in Haematology. Transfus Med. 2013;23:3-35.
Davis BA, Allard S, Qureshi A, et al.; British Committee for Standards in, H. Guidelines on red cell transfusion in sickle cell disease. Part I: principles and laboratory aspects. Br J Haematol. 2017;176:179-191.
Chou S, Jackson T, Vege S, Smith Whitley K, Friedman D, Westhoff C. High prevalence of red blood cell alloimmunization in sickle cell disease despite transfusion from Rh-matched minority donors. Blood. 2013;122:1062-1071.
Compernolle V, Chou ST, Tanael S, et al. Red blood cell specifications for patients with hemoglobinopathies: a systematic review and guideline. Transfusion. 2018;58:1555-1566.
Trompeter S, Massey EJ, Robinson S. Position paper on International Collaboration for Transfusion Medicine Guideline ‘Red blood specifications for patients with haemoglobinopathies: a systematic review and guideline’. Br J Haematol. 2020;189(3):424-427.
Matteocci A, Pierelli L. Red blood cell alloimmunization in sickle cell disease and in thalassaemia: current status, future perspectives and potential role of molecular typing. Vox Sang. 2014;106:197-208.
Public Health England. NHS Sickle Cell and Thalassaemia Screening Programme. Data Report 2016-17: Trends and Performance Analysis; 2018. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/713120/SCT_data_report_2016_to_2017.pdf. Accessed 1 October 2020.
Abboud MR, Yim E, Musallam KM, Adams RJ. Discontinuing prophylactic transfusions increases the risk of silent brain infarction in children with sickle cell disease: data from STOP II. Blood. 2011;118:894-898.
DeBaun MR, Casella JF. Transfusions for silent cerebral infarcts in sickle cell anemia. N Engl J Med. 2014;371:1841-1842.
Pegelow CH, Adams RJ, McKie V, et al. Risk of recurrent stroke in patients with sickle cell disease treated with erythrocyte transfusions. J Pediatr. 1995;126:896-899.
Reed WF, Vichinsky EP. Transfusion practice for patients with sickle cell disease. Curr Opin Hematol. 1999;6:432-436.
Molesworth A, Yates P, Hewitt P, et al. Investigation of variant Creutzfeldt-Jakob disease implicated organ or tissue transplantation in the United Kingdom. Transplantation. 2014;98:585-589.
Hewitt PE, Ijaz S, Brailsford SR, et al. Hepatitis E virus in blood components: a prevalence and transmission study in southeast England. Lancet. 2014;384:1766-1773.
Chapman JF, Elliott C, Knowles SM, Milkins CE, Poole GD; Working Party of the British Committee for Standards in Haematology Blood Transfusion Task, F. Guidelines for compatibility procedures in blood transfusion laboratories. Transfus Med. 2004;14:59-73.
Serious Hazards of Transfusion, S.H. of T. Definitions of Current Serious Hazards of Transfusion Reporting Categories and What to Report; 2019. https://www.shotuk.org/wp-content/uploads/myimages/SHOT-Definitions-update-10.01.20-FINAL.pdf. Accessed 1 October 2020.
National Haemoglobinopathy Registry. National Haemoglobinopathy Registry Annual Report 2018/9; 2019. http://nhr.mdsas.com/wp-content/uploads/2019/06/NHR_AnnualReport201819.pdf. Accessed 1 October 2020.
Trompeter S, Bolton-Maggs P, Ryan K, et al. National comparative audit of blood transfusion: 2014 audit of transfusion services and practice in children and adults with sickle cell disease. Transfus Med. Accessed 1 October 2020.
National Haemoglobinopathy Registry. NHR Information Service: Number of patients by diagnosis; 2019. http://nhr.mdsas.com/wp-content/uploads/2019/11/NumberPatientsDiagnosis.pdf. Accessed 1 October 2020.
Kim H. Red cell exchange: special focus on sickle cell disease. Hematology. 2014;2014:450-456.
National Institute for Health and Care Excellence. Spectra Optia for Automatic Red Blood Cell Exchange in Patients with Sickle Cell Disease (MTG28): Evidence-Based Recommendations on Spectra Optia for Automated Red Blood Cell Exchange in Patients with Sickle Cell Disease March 2016; 2016. https://www.nice.org.uk/guidance/mtg28. Accessed 1 October 2020.
NHS England. Specialised Commissioning: Improving Specialised Services for Sickle Cell, Thalassaemia and Other Rare Inherited Anaemias; 2018. https://www.engage.england.nhs.uk/survey/554310d8/supporting_documents/haemoglobinopathyservicereviewjune2018.pdf. Accessed 1 October 2020.
Trompeter S, Garbowski M, Bailey C, Huntley N. Red cell depletion in automated red cell exchange: a safe and effective method of exchange transfusion whilst reducing blood usage. Paper presented at: British Society of Haematology Annual Conference, 2015.
Adams RJ, McKie VC, Hsu L, et al. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial doppler ultrasonography. N Engl J Med. 1998b;339:5-11.
Adams RJ, McKie VC, Brambilla D, et al. Stroke prevention trial in sickle cell anemia. Control Clin Trials. 1998a;19:110-129.
Ware RE, Davis BR, Schultz WH, et al. Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia-TCD With Transfusions Changing to Hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial. Lancet. 2016;387:661-670.
Ware RE, Helms RW, Investigators SW. Stroke With Transfusions Changing to Hydroxyurea (SWiTCH). Blood. 2012;119:3925-3932.